Alnylam Pharmaceuticals, Inc. (ALNY) Earns Reduce Rating from Analysts at Nomura

Analysts at Nomura initiated coverage on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report issued to clients and investors on Thursday. The firm set a “reduce” rating and a $56.00 price target on the biopharmaceutical company’s stock. Nomura’s price target would suggest a potential downside of 28.39% from the company’s previous close.

Other analysts have also issued reports about the stock. Morgan Stanley reiterated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. BidaskClub lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 16th. Ladenburg Thalmann Financial Services set a $80.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 17th. J P Morgan Chase & Co reiterated a “hold” rating on shares of Alnylam Pharmaceuticals in a report on Monday, June 26th. Finally, Chardan Capital reiterated a “buy” rating and set a $131.00 target price (up from $110.00) on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $82.25.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down 2.94% on Thursday, hitting $78.20. The stock had a trading volume of 683,025 shares. The firm’s market capitalization is $7.17 billion. The firm has a 50 day moving average of $81.65 and a 200-day moving average of $68.34. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $89.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). The firm had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.05) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals will post ($5.18) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals, Inc. (ALNY) Earns Reduce Rating from Analysts at Nomura” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2017/09/14/alnylam-pharmaceuticals-inc-alny-earns-reduce-rating-from-analysts-at-nomura.html.

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after purchasing an additional 815,270 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after purchasing an additional 31,208 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 13.4% during the second quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after purchasing an additional 759,295 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 9.3% during the second quarter. BlackRock Inc. now owns 5,188,191 shares of the biopharmaceutical company’s stock valued at $413,811,000 after purchasing an additional 441,957 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.9% during the second quarter. Baillie Gifford & Co. now owns 3,431,316 shares of the biopharmaceutical company’s stock valued at $273,681,000 after purchasing an additional 96,805 shares during the last quarter. Hedge funds and other institutional investors own 94.27% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply